Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis

This prespecified subgroup analysis of a phase 3 randomized controlled trial evaluated the impact of adding evolocumab to optimally tolerated statin therapy in high-risk patients with type 2 diabetes who did not have known significant atherosclerosis and no prior myocardial infarction or stroke. The study was conducted across 774 sites in 33 countries. The population included patients with diabetes, an LDL-C level of 90 mg/dL or greater, and either qualifying atherosclerosis or high-risk diabetes. The total sample size was 3655 participants, with 1849 assigned to evolocumab and 1806 to placebo.

The intervention consisted of evolocumab 140 mg administered subcutaneously every 2 weeks, added to optimally tolerated statin therapy. The comparator was matching placebo added to optimally tolerated statin therapy. Treatment was continued for the duration of the trial, and participants were followed for a median of 4.8 years (57.6 months). The trial used standard double-blinding procedures and centralized randomization, consistent with the parent study design.

The dual primary endpoints were a composite of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and the same 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). For 3-P MACE, an event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group versus 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group. The hazard ratio was 0.69 (95% CI, 0.52-0.91; P = .009), with a between-group difference of 2.1% (95% CI, 0.4%-3.8%). For 4-P MACE, an event occurred in 127 patients (5-year Kaplan-Meier estimate, 7.6%) in the evolocumab group versus 178 patients (5-year Kaplan-Meier estimate, 10.5%) in the placebo group. The hazard ratio was 0.69 (95% CI, 0.55-0.86; P = .001), with a between-group difference of 2.9% (95% CI, 0.9%-4.9%). These results indicate a statistically significant reduction in both primary endpoints with evolocumab.

A key secondary outcome was all-cause mortality. There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group versus 172 deaths (5-year Kaplan-Meier estimate, 10.1%) in the placebo group. The hazard ratio was 0.76 (95% CI, 0.61-0.95), indicating a significant reduction in mortality. The absolute numbers for the between-group difference were not reported. These findings extend the primary trial results by showing mortality benefit in this subgroup, although the analysis is prespecified and not the primary trial analysis.

Safety and tolerability data were not reported in the provided evidence, including adverse events, serious adverse events, and discontinuations. Therefore, the safety profile of evolocumab in this specific subgroup cannot be characterized from this summary. Clinicians should refer to the parent trial and other safety databases for information on injection-site reactions, neurocognitive events, and other potential adverse effects associated with PCSK9 inhibitors.

These results are consistent with prior landmark PCSK9 inhibitor trials that demonstrated LDL-C lowering and cardiovascular event reduction in broader populations with established atherosclerotic cardiovascular disease or high-risk primary prevention. The magnitude of relative risk reduction (HR 0.69 for both 3-P and 4-P MACE) aligns with earlier evolocumab trials, but the absolute risk reduction in this subgroup (2.1% to 2.9% over 5 years) reflects the baseline risk of the enrolled population. The mortality finding (HR 0.76) is notable and adds to the evidence base, although it should be interpreted within the context of subgroup analysis.

Key methodological limitations include the prespecified subgroup nature of the analysis, which reduces statistical power and increases the risk of type I error compared with the primary trial analysis. Results apply specifically to patients without known significant atherosclerosis and with diabetes, and may not generalize to patients with established atherosclerotic disease or those with lower baseline LDL-C. The absence of reported safety data in this summary limits a full risk-benefit assessment. The study does not address whether evolocumab should be initiated before or after achieving statin optimization, or how it compares with other non-statin therapies in this population.

For practice decisions, these findings support consideration of evolocumab in high-risk patients with type 2 diabetes without known significant atherosclerosis who have LDL-C levels of 90 mg/dL or greater despite maximally tolerated statin therapy. Clinicians should weigh the observed reductions in major cardiovascular events and all-cause mortality against the lack of reported safety data and the subgroup nature of the analysis. Shared decision-making should include discussion of patient preferences, cost considerations, and access to PCSK9 inhibitors. Further questions remain regarding long-term safety, durability of benefit, and comparative effectiveness against other non-statin therapies in this specific population.